Figure 3From: Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension Changes in maximal expiratory flow (MEF) at (a) 75%, (b) 50%, (c) 25% of remaining vital capacity after 3 and 12 months of treatment in 32 patients with IPAH.Back to article page